Bristol Myers Squibb and immunotherapy developer Janux Therapeutics have announced a collaboration and exclusive worldwide license agreement. Under the terms of the agreement, the companies will develop an undisclosed, novel, tumour-activated therapeutic targeting a validated solid tumour antigen expressed across several human cancer types. Janux may receive up to $50 million in upfront and near-term […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!